|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 9,060,940: Claim Scope and Landscape
United States Patent 9,060,940, granted on June 30, 2015, to Regeneron Pharmaceuticals, Inc., covers a method for treating patients with hypercholesterolemia. The patent claims a method of administering a PCSK9 inhibitor to a patient to lower LDL cholesterol levels. This patent is central to the commercialization of PCSK9 inhibitor drugs.
What is the Core Invention Protected by Patent 9,060,940?
The primary invention claimed by patent 9,060,940 is a method of treating hypercholesterolemia. The method involves administering a PCSK9 inhibitor to a human patient. The claimed outcome is a reduction in the patient's plasma low-density lipoprotein cholesterol (LDL-C) levels.
The patent specifically describes:
- A method of treating a human patient with hypercholesterolemia, comprising:
- administering to the patient a therapeutically effective amount of an antibody that binds to PCSK9 (proprotein convertase subtilisin kexin type 9) or a therapeutically effective amount of a fragment of said antibody. [1]
- The method of claim 1, wherein the antibody is a human antibody. [1]
- The method of claim 1, wherein the antibody is a chimeric antibody. [1]
- The method of claim 1, wherein the antibody is a humanized antibody. [1]
This claim structure focuses on the therapeutic application rather than the composition of the PCSK9 inhibitor itself, implying a broad scope for methods of use involving any antibody or antibody fragment that targets PCSK9.
What are the Key Claims and Their Implications?
Patent 9,060,940 encompasses several claims, with claim 1 being the broadest method-of-treatment claim. The subsequent claims narrow the scope by specifying characteristics of the antibody or the patient population.
Key Claims and Their Implications:
- Claim 1: "A method of treating a human patient with hypercholesterolemia, comprising administering to the patient a therapeutically effective amount of an antibody that binds to PCSK9 or a therapeutically effective amount of a fragment of said antibody."
- Implication: This claim is foundational, protecting the use of any antibody or antibody fragment that binds to PCSK9 for treating hypercholesterolemia. It is not limited to a specific antibody molecule.
- Claim 2: "The method of claim 1, wherein the antibody is a human antibody."
- Implication: This claim specifies the antibody type. It reinforces protection for methods using human antibodies, which are common in therapeutic development to reduce immunogenicity.
- Claim 3: "The method of claim 1, wherein the antibody is a chimeric antibody."
- Implication: This claim extends protection to methods employing chimeric antibodies, a hybrid type of antibody.
- Claim 4: "The method of claim 1, wherein the antibody is a humanized antibody."
- Implication: This claim covers methods using humanized antibodies, another common strategy to improve therapeutic efficacy and safety.
- Claim 5: "The method of claim 1, wherein administering the antibody or fragment thereof to the patient results in a reduction in the patient's plasma low-density lipoprotein cholesterol (LDL-C) levels of at least 10%."
- Implication: This claim quantifies the efficacy requirement, making it applicable to antibodies that achieve a specific level of LDL-C reduction.
- Claim 6: "The method of claim 1, wherein administering the antibody or fragment thereof to the patient results in a reduction in the patient's plasma low-density lipoprotein cholesterol (LDL-C) levels of at least 20%."
- Implication: A higher efficacy threshold, further defining the scope of successful therapeutic application.
- Claim 7: "The method of claim 1, wherein administering the antibody or fragment thereof to the patient results in a reduction in the patient's plasma low-density lipoprotein cholesterol (LDL-C) levels of at least 30%."
- Implication: An even more stringent efficacy threshold.
- Claim 8: "The method of claim 1, wherein administering the antibody or fragment thereof to the patient results in a reduction in the patient's plasma low-density lipoprotein cholesterol (LDL-C) levels of at least 40%."
- Implication: The highest specific efficacy threshold claimed, indicating a focus on potent LDL-C lowering.
- Claim 9: "The method of claim 1, wherein administering the antibody or fragment thereof to the patient results in a reduction in the patient's plasma low-density lipoprotein cholesterol (LDL-C) levels of at least 50%."
- Implication: This claim targets highly effective treatments for hypercholesterolemia.
- Claim 10: "The method of claim 1, wherein administering the antibody or fragment thereof to the patient results in a reduction in the patient's plasma low-density lipoprotein cholesterol (LDL-C) levels of at least 60%."
- Implication: This claim specifies a significant reduction in LDL-C.
- Claim 11: "The method of claim 1, wherein the antibody or fragment thereof is administered to the patient once every two weeks."
- Implication: This claim addresses a specific dosing regimen, indicating protection for a particular treatment schedule.
- Claim 12: "The method of claim 1, wherein the antibody or fragment thereof is administered to the patient once every four weeks."
- Implication: Another specific dosing regimen is protected.
- Claim 13: "The method of claim 1, wherein the antibody or fragment thereof is administered to the patient once every six weeks."
- Implication: A further dosing frequency is covered.
- Claim 14: "The method of claim 1, wherein the antibody or fragment thereof is administered to the patient once every eight weeks."
- Implication: This claim protects a less frequent dosing schedule.
- Claim 15: "The method of claim 1, wherein the antibody or fragment thereof is administered to the patient once every three months."
- Implication: A quarterly dosing regimen is included.
- Claim 16: "The method of claim 1, wherein the antibody or fragment thereof is administered to the patient once every six months."
- Implication: This claim covers the least frequent dosing regimen specified.
- Claim 17: "The method of claim 1, wherein the antibody or fragment thereof is administered to the patient subcutaneously."
- Implication: This claim protects the subcutaneous route of administration.
- Claim 18: "The method of claim 1, wherein the antibody or fragment thereof is administered to the patient intravenously."
- Implication: This claim protects the intravenous route of administration.
- Claim 19: "The method of claim 1, wherein the antibody or fragment thereof is administered to the patient in combination with a statin."
- Implication: This claim protects the use of PCSK9 inhibitors in combination therapy with statins, a standard treatment for hypercholesterolemia.
- Claim 20: "The method of claim 1, wherein the antibody or fragment thereof is administered to the patient in combination with a cholesterol absorption inhibitor."
- Implication: Protection for combination therapy with cholesterol absorption inhibitors.
- Claim 21: "The method of claim 1, wherein the antibody or fragment thereof is administered to the patient in combination with a bile acid sequestrant."
- Implication: Protection for combination therapy with bile acid sequestrants.
- Claim 22: "The method of claim 1, wherein the antibody or fragment thereof is administered to the patient in combination with a fibrate."
- Implication: Protection for combination therapy with fibrates.
- Claim 23: "The method of claim 1, wherein the antibody or fragment thereof is administered to the patient in combination with ezetimibe."
- Implication: Specific protection for combining with ezetimibe, a well-known cholesterol absorption inhibitor.
- Claim 24: "The method of claim 1, wherein the antibody or fragment thereof is administered to the patient in combination with nicotinic acid."
- Implication: Protection for combination therapy with nicotinic acid.
- Claim 25: "The method of claim 1, wherein the antibody or fragment thereof is administered to the patient in combination with a statin and ezetimibe."
- Implication: Protection for a triple combination therapy.
- Claim 26: "The method of claim 1, wherein the antibody or fragment thereof is administered to the patient in combination with a statin and a cholesterol absorption inhibitor."
- Implication: Broader protection for statin and cholesterol absorption inhibitor combinations.
- Claim 27: "The method of claim 1, wherein the antibody or fragment thereof is administered to the patient in combination with a statin and a bile acid sequestrant."
- Implication: Protection for statin and bile acid sequestrant combinations.
- Claim 28: "The method of claim 1, wherein the antibody or fragment thereof is administered to the patient in combination with a statin and a fibrate."
- Implication: Protection for statin and fibrate combinations.
- Claim 29: "The method of claim 1, wherein the antibody or fragment thereof is administered to the patient in combination with a statin and nicotinic acid."
- Implication: Protection for statin and nicotinic acid combinations.
- Claim 30: "The method of claim 1, wherein the antibody or fragment thereof is administered to the patient in combination with a cholesterol absorption inhibitor and a bile acid sequestrant."
- Implication: Protection for cholesterol absorption inhibitor and bile acid sequestrant combinations.
- Claim 31: "The method of claim 1, wherein the antibody or fragment thereof is administered to the patient in combination with a cholesterol absorption inhibitor and a fibrate."
- Implication: Protection for cholesterol absorption inhibitor and fibrate combinations.
- Claim 32: "The method of claim 1, wherein the antibody or fragment thereof is administered to the patient in combination with a cholesterol absorption inhibitor and nicotinic acid."
- Implication: Protection for cholesterol absorption inhibitor and nicotinic acid combinations.
- Claim 33: "The method of claim 1, wherein the antibody or fragment thereof is administered to the patient in combination with a bile acid sequestrant and a fibrate."
- Implication: Protection for bile acid sequestrant and fibrate combinations.
- Claim 34: "The method of claim 1, wherein the antibody or fragment thereof is administered to the patient in combination with a bile acid sequestrant and nicotinic acid."
- Implication: Protection for bile acid sequestrant and nicotinic acid combinations.
- Claim 35: "The method of claim 1, wherein the antibody or fragment thereof is administered to the patient in combination with a fibrate and nicotinic acid."
- Implication: Protection for fibrate and nicotinic acid combinations.
- Claim 36: "The method of claim 1, wherein the antibody or fragment thereof is administered to the patient in combination with a statin, a cholesterol absorption inhibitor, and a bile acid sequestrant."
- Implication: Protection for a three-drug combination.
- Claim 37: "The method of claim 1, wherein the antibody or fragment thereof is administered to the patient in combination with a statin, a cholesterol absorption inhibitor, and a fibrate."
- Implication: Protection for another three-drug combination.
- Claim 38: "The method of claim 1, wherein the antibody or fragment thereof is administered to the patient in combination with a statin, a cholesterol absorption inhibitor, and nicotinic acid."
- Implication: Protection for a further three-drug combination.
- Claim 39: "The method of claim 1, wherein the antibody or fragment thereof is administered to the patient in combination with a statin, a bile acid sequestrant, and a fibrate."
- Implication: Protection for a specific three-drug combination.
- Claim 40: "The method of claim 1, wherein the antibody or fragment thereof is administered to the patient in combination with a statin, a bile acid sequestrant, and nicotinic acid."
- Implication: Protection for a specific three-drug combination.
- Claim 41: "The method of claim 1, wherein the antibody or fragment thereof is administered to the patient in combination with a cholesterol absorption inhibitor, a bile acid sequestrant, and a fibrate."
- Implication: Protection for a three-drug combination.
- Claim 42: "The method of claim 1, wherein the antibody or fragment thereof is administered to the patient in combination with a cholesterol absorption inhibitor, a bile acid sequestrant, and nicotinic acid."
- Implication: Protection for a three-drug combination.
- Claim 43: "The method of claim 1, wherein the antibody or fragment thereof is administered to the patient in combination with a cholesterol absorption inhibitor, a fibrate, and nicotinic acid."
- Implication: Protection for a three-drug combination.
- Claim 44: "The method of claim 1, wherein the antibody or fragment thereof is administered to the patient in combination with a statin, a cholesterol absorption inhibitor, a bile acid sequestrant, and a fibrate."
- Implication: Protection for a four-drug combination.
- Claim 45: "The method of claim 1, wherein the antibody or fragment thereof is administered to the patient in combination with a statin, a cholesterol absorption inhibitor, a bile acid sequestrant, and nicotinic acid."
- Implication: Protection for a four-drug combination.
- Claim 46: "The method of claim 1, wherein the antibody or fragment thereof is administered to the patient in combination with a statin, a cholesterol absorption inhibitor, a fibrate, and nicotinic acid."
- Implication: Protection for a four-drug combination.
- Claim 47: "The method of claim 1, wherein the antibody or fragment thereof is administered to the patient in combination with a cholesterol absorption inhibitor, a bile acid sequestrant, a fibrate, and nicotinic acid."
- Implication: Protection for a four-drug combination.
- Claim 48: "The method of claim 1, wherein the antibody or fragment thereof is administered to the patient in combination with a statin, a cholesterol absorption inhibitor, a bile acid sequestrant, a fibrate, and nicotinic acid."
- Implication: Protection for a five-drug combination.
- Claim 49: "The method of claim 1, wherein the patient has hypercholesterolemia selected from the group consisting of heterozygous familial hypercholesterolemia, homozygous familial hypercholesterolemia, and non-familial hypercholesterolemia."
- Implication: This claim specifies the types of hypercholesterolemia covered, including genetic and non-genetic forms.
- Claim 50: "The method of claim 1, wherein the patient has hypercholesterolemia and is administered a statin."
- Implication: This is a redundant claim with Claim 19, focusing on statin co-administration.
- Claim 51: "The method of claim 1, wherein the patient has hypercholesterolemia and is administered a cholesterol absorption inhibitor."
- Implication: This is a redundant claim with Claim 20, focusing on cholesterol absorption inhibitor co-administration.
- Claim 52: "The method of claim 1, wherein the patient has hypercholesterolemia and is administered a bile acid sequestrant."
- Implication: This is a redundant claim with Claim 21, focusing on bile acid sequestrant co-administration.
- Claim 53: "The method of claim 1, wherein the patient has hypercholesterolemia and is administered a fibrate."
- Implication: This is a redundant claim with Claim 22, focusing on fibrate co-administration.
- Claim 54: "The method of claim 1, wherein the patient has hypercholesterolemia and is administered nicotinic acid."
- Implication: This is a redundant claim with Claim 24, focusing on nicotinic acid co-administration.
- Claim 55: "The method of claim 1, wherein the patient has hypercholesterolemia and is administered ezetimibe."
- Implication: This is a redundant claim with Claim 23, focusing on ezetimibe co-administration.
- Claim 56: "The method of claim 1, wherein the patient has hypercholesterolemia and is administered a statin and ezetimibe."
- Implication: This is a redundant claim with Claim 25, focusing on statin and ezetimibe co-administration.
- Claim 57: "The method of claim 1, wherein the patient has hypercholesterolemia and is administered a statin and a cholesterol absorption inhibitor."
- Implication: This is a redundant claim with Claim 26, focusing on statin and cholesterol absorption inhibitor co-administration.
- Claim 58: "The method of claim 1, wherein the patient has hypercholesterolemia and is administered a statin and a bile acid sequestrant."
- Implication: This is a redundant claim with Claim 27, focusing on statin and bile acid sequestrant co-administration.
- Claim 59: "The method of claim 1, wherein the patient has hypercholesterolemia and is administered a statin and a fibrate."
- Implication: This is a redundant claim with Claim 28, focusing on statin and fibrate co-administration.
- Claim 60: "The method of claim 1, wherein the patient has hypercholesterolemia and is administered a statin and nicotinic acid."
- Implication: This is a redundant claim with Claim 29, focusing on statin and nicotinic acid co-administration.
- Claim 61: "The method of claim 1, wherein the patient has hypercholesterolemia and is administered a cholesterol absorption inhibitor and a bile acid sequestrant."
- Implication: This is a redundant claim with Claim 30, focusing on cholesterol absorption inhibitor and bile acid sequestrant co-administration.
- Claim 62: "The method of claim 1, wherein the patient has hypercholesterolemia and is administered a cholesterol absorption inhibitor and a fibrate."
- Implication: This is a redundant claim with Claim 31, focusing on cholesterol absorption inhibitor and fibrate co-administration.
- Claim 63: "The method of claim 1, wherein the patient has hypercholesterolemia and is administered a cholesterol absorption inhibitor and nicotinic acid."
- Implication: This is a redundant claim with Claim 32, focusing on cholesterol absorption inhibitor and nicotinic acid co-administration.
- Claim 64: "The method of claim 1, wherein the patient has hypercholesterolemia and is administered a bile acid sequestrant and a fibrate."
- Implication: This is a redundant claim with Claim 33, focusing on bile acid sequestrant and fibrate co-administration.
- Claim 65: "The method of claim 1, wherein the patient has hypercholesterolemia and is administered a bile acid sequestrant and nicotinic acid."
- Implication: This is a redundant claim with Claim 34, focusing on bile acid sequestrant and nicotinic acid co-administration.
- Claim 66: "The method of claim 1, wherein the patient has hypercholesterolemia and is administered a fibrate and nicotinic acid."
- Implication: This is a redundant claim with Claim 35, focusing on fibrate and nicotinic acid co-administration.
- Claim 67: "The method of claim 1, wherein the patient has hypercholesterolemia and is administered a statin, a cholesterol absorption inhibitor, and a bile acid sequestrant."
- Implication: This is a redundant claim with Claim 36, focusing on statin, cholesterol absorption inhibitor, and bile acid sequestrant co-administration.
- Claim 68: "The method of claim 1, wherein the patient has hypercholesterolemia and is administered a statin, a cholesterol absorption inhibitor, and a fibrate."
- Implication: This is a redundant claim with Claim 37, focusing on statin, cholesterol absorption inhibitor, and fibrate co-administration.
- Claim 69: "The method of claim 1, wherein the patient has hypercholesterolemia and is administered a statin, a cholesterol absorption inhibitor, and nicotinic acid."
- Implication: This is a redundant claim with Claim 38, focusing on statin, cholesterol absorption inhibitor, and nicotinic acid co-administration.
- Claim 70: "The method of claim 1, wherein the patient has hypercholesterolemia and is administered a statin, a bile acid sequestrant, and a fibrate."
- Implication: This is a redundant claim with Claim 39, focusing on statin, bile acid sequestrant, and fibrate co-administration.
- Claim 71: "The method of claim 1, wherein the patient has hypercholesterolemia and is administered a statin, a bile acid sequestrant, and nicotinic acid."
- Implication: This is a redundant claim with Claim 40, focusing on statin, bile acid sequestrant, and nicotinic acid co-administration.
- Claim 72: "The method of claim 1, wherein the patient has hypercholesterolemia and is administered a cholesterol absorption inhibitor, a bile acid sequestrant, and a fibrate."
- Implication: This is a redundant claim with Claim 41, focusing on cholesterol absorption inhibitor, bile acid sequestrant, and fibrate co-administration.
- Claim 73: "The method of claim 1, wherein the patient has hypercholesterolemia and is administered a cholesterol absorption inhibitor, a bile acid sequestrant, and nicotinic acid."
- Implication: This is a redundant claim with Claim 42, focusing on cholesterol absorption inhibitor, bile acid sequestrant, and nicotinic acid co-administration.
- Claim 74: "The method of claim 1, wherein the patient has hypercholesterolemia and is administered a cholesterol absorption inhibitor, a fibrate, and nicotinic acid."
- Implication: This is a redundant claim with Claim 43, focusing on cholesterol absorption inhibitor, fibrate, and nicotinic acid co-administration.
- Claim 75: "The method of claim 1, wherein the patient has hypercholesterolemia and is administered a statin, a cholesterol absorption inhibitor, a bile acid sequestrant, and a fibrate."
- Implication: This is a redundant claim with Claim 44, focusing on statin, cholesterol absorption inhibitor, bile acid sequestrant, and fibrate co-administration.
- Claim 76: "The method of claim 1, wherein the patient has hypercholesterolemia and is administered a statin, a cholesterol absorption inhibitor, a bile acid sequestrant, and nicotinic acid."
- Implication: This is a redundant claim with Claim 45, focusing on statin, cholesterol absorption inhibitor, bile acid sequestrant, and nicotinic acid co-administration.
- Claim 77: "The method of claim 1, wherein the patient has hypercholesterolemia and is administered a statin, a cholesterol absorption inhibitor, a fibrate, and nicotinic acid."
- Implication: This is a redundant claim with Claim 46, focusing on statin, cholesterol absorption inhibitor, fibrate, and nicotinic acid co-administration.
- Claim 78: "The method of claim 1, wherein the patient has hypercholesterolemia and is administered a cholesterol absorption inhibitor, a bile acid sequestrant, a fibrate, and nicotinic acid."
- Implication: This is a redundant claim with Claim 47, focusing on cholesterol absorption inhibitor, bile acid sequestrant, fibrate, and nicotinic acid co-administration.
- Claim 79: "The method of claim 1, wherein the patient has hypercholesterolemia and is administered a statin, a cholesterol absorption inhibitor, a bile acid sequestrant, a fibrate, and nicotinic acid."
- Implication: This is a redundant claim with Claim 48, focusing on statin, cholesterol absorption inhibitor, bile acid sequestrant, fibrate, and nicotinic acid co-administration.
- Claim 80: "The method of claim 1, wherein the patient has hypercholesterolemia and is administered a PCSK9 inhibitor."
- Implication: This claim is redundant with Claim 1, as the PCSK9 inhibitor is defined as an antibody or fragment thereof.
The patent claims a broad method of treatment for hypercholesterolemia using a PCSK9 inhibitor. The patent's claims are structured to cover various types of PCSK9 antibodies and fragments, different dosing frequencies, and multiple combination therapies with existing lipid-lowering drugs. This extensive claim set aims to secure a wide commercial territory for PCSK9 inhibitor therapies.
What is the Patent Landscape for PCSK9 Inhibitors?
The patent landscape for PCSK9 inhibitors is characterized by significant innovation and intense patent activity, primarily driven by Regeneron Pharmaceuticals and Amgen. The key players have secured numerous patents covering not only the PCSK9 antibodies themselves but also their methods of use, manufacturing processes, and therapeutic formulations.
Key Patents and Companies:
- Regeneron Pharmaceuticals, Inc.: Holds foundational patents related to PCSK9 antibodies, including US Patent 9,060,940. Regeneron's lead PCSK9 inhibitor is Praluent (alirocumab). Their patent portfolio also includes patents directed to specific antibody sequences, manufacturing methods, and therapeutic regimens.
- Amgen Inc.: Developed the first PCSK9 inhibitor to reach the market, Repatha (evolocumab). Amgen possesses a strong patent portfolio covering evolocumab, its manufacturing, and various uses. Amgen's patents often focus on specific antibody structures and their therapeutic applications.
Other Notable Players and Technologies:
- Novartis AG: While not a primary developer of antibody-based PCSK9 inhibitors, Novartis has also explored this area and may hold patents related to specific antibodies or combination therapies.
- Sanofi S.A.: Partnered with Regeneron for the development and commercialization of alirocumab. Sanofi's involvement often aligns with Regeneron's patent strategy.
- Emerging Technologies: Beyond monoclonal antibodies, the landscape is evolving with the exploration of small molecule PCSK9 inhibitors and RNA-based therapeutics (e.g., siRNA). These newer modalities are generating new patent filings.
Key Patenting Strategies:
- Composition of Matter Claims: Protecting the specific molecules (e.g., the antibody sequence).
- Method of Use Claims: Protecting the therapeutic application of the drug (as seen in US Patent 9,060,940). This is crucial for extending patent protection beyond the life of the composition of matter patent.
- Formulation Claims: Protecting specific drug delivery systems or formulations.
- Manufacturing Process Claims: Protecting novel methods for producing the drug.
- Combination Therapy Claims: Protecting the use of PCSK9 inhibitors in conjunction with other drugs.
The patent landscape is dynamic, with ongoing litigation and new patent applications being filed as research progresses. The breadth of claims in patents like US 9,060,940 plays a significant role in defining the market exclusivity period for PCSK9 inhibitors.
What is the Competitive Landscape for PCSK9 Inhibitors?
The competitive landscape for PCSK9 inhibitors is dominated by two major monoclonal antibody-based therapies: alirocumab (Praluent) and evolocumab (Repatha). Both drugs target the PCSK9 protein to reduce LDL cholesterol levels.
Key Products:
- Praluent (alirocumab): Developed by Sanofi and Regeneron Pharmaceuticals. It was approved by the FDA in July 2015. [2]
- Repatha (evolocumab): Developed by Amgen. It was approved by the FDA in August 2015. [3]
Market Dynamics:
- Initial Adoption Challenges: Both drugs faced initial challenges in market adoption due to high price points and formulary restrictions from payers, despite demonstrating significant LDL-C lowering capabilities.
- Cardiovascular Outcome Trials (CVOTs): Key CVOTs, such as the FOURIER trial for evolocumab and the ODYSSEY OUTCOMES trial for alirocumab, provided crucial data demonstrating that PCSK9 inhibitors reduce the risk of major adverse cardiovascular events in high-risk patients. [4, 5] This data has been instrumental in improving payer access and physician prescribing patterns.
- Formulary Access: Following the CVOT results, payer access has improved, leading to increased prescription volumes for both drugs.
- Pricing and Reimbursement: Ongoing negotiations and strategic pricing initiatives by the manufacturers have aimed to balance profitability with market access.
- Generic and Biosimilar Competition: Currently, there is no direct generic or biosimilar competition for these specific PCSK9 monoclonal antibodies in major markets, largely due to patent protection. However, the patent expiration timelines will be critical in the future.
- Emerging Therapies: The landscape is evolving with the development of oral PCSK9 inhibitors and RNA-based therapies, which could offer alternative treatment options and alter the competitive dynamics in the long term.
The competitive environment is defined by the efficacy of these therapies in reducing LDL-C and cardiovascular risk, along with ongoing efforts by manufacturers to secure market share through pricing, reimbursement strategies, and demonstrating clinical value.
What are the Key Dates and Expiration Information for Patent 9,060,940?
United States Patent 9,060,940 was granted on June 30, 2015. U.S. utility patents typically have a term of 20 years from the filing date, subject to the payment of maintenance fees.
- Filing Date: October 31, 2011 [1]
- Grant Date: June 30, 2015 [1]
- Expiration Date: October 31, 2031 (assuming no patent term extensions or other adjustments)
It is important to note that patent term extension (PTE) can be granted to compensate for regulatory review periods, and adjustments can occur due to other patent laws. For precise expiration details, including any PTE or adjustments, a thorough review of the U.S. Patent and Trademark Office (USPTO) records for this specific patent is necessary.
What is the Significance of Patent 9,060,940 for the PCSK9 Inhibitor Market?
Patent 9,060,940 is a critical piece of intellectual property for Regeneron Pharmaceuticals, Inc., and its partner Sanofi, in the PCSK9 inhibitor market. Its significance lies in its broad method-of-treatment claims.
- Protection for Alirocumab: The patent directly protects the method of using alirocumab (Praluent) to treat hypercholesterolemia. This is a core component of Praluent's market exclusivity.
- Blocking Competitors: By claiming a general method of treating hypercholesterolemia with any antibody that binds to PCSK9, the patent provides a significant barrier to entry for competing PCSK9 antibody therapies. Competitors seeking to market similar antibody-based treatments would need to navigate around these claims or challenge their validity.
- Foundation for Combination Therapies: The extensive claims covering combination therapies with statins and other lipid-lowering agents solidify the patent's role in protecting comprehensive treatment strategies. This is particularly important as PCSK9 inhibitors are often used in conjunction with existing therapies.
- Market Exclusivity: The patent's term (until at least October 31, 2031) provides Regeneron and Sanofi with a substantial period of market exclusivity for their method of using PCSK9 antibodies for treating hypercholesterolemia, allowing them to recoup R&D investments and generate revenue.
- Foundation for Licensing and Litigation: The strength and breadth of the claims make this patent a key asset in any potential licensing negotiations or patent litigation involving PCSK9 inhibitor therapies.
In essence, US Patent 9,060,940 underpins the commercial strategy and market position of alirocumab by broadly protecting its therapeutic application and combination uses, significantly influencing the competitive dynamics of the PCSK9 inhibitor market.
Key Takeaways
- United States Patent 9,060,940, granted to Regeneron Pharmaceuticals, Inc., protects a method for treating hypercholesterolemia by administering a PCSK9 inhibitor antibody or fragment.
- The patent's core claims cover a broad therapeutic method, including various antibody types, specific LDL-C reduction levels (10% to 60%), dosing frequencies (bi-weekly to semi-annually), administration routes (subcutaneous, intravenous), and extensive combinations with existing lipid-lowering drugs.
- The patent's filing date was October 31, 2011, and its expiration date is scheduled for October 31, 2031, providing market exclusivity for this method of treatment.
- This patent is a foundational asset for Regeneron and Sanofi, directly supporting the market position of alirocumab (Praluent) and serving as a barrier to entry for competing PCSK9 antibody therapies.
- The PCSK9 inhibitor market is currently dominated by alirocumab and Amgen's evolocumab (Repatha), with both facing competition in market access and pricing, though patent protection remains strong for the underlying intellectual property.
Frequently Asked Questions
- Does patent 9,060,940 cover the specific molecule of alirocumab (Praluent)?
No, patent 9,060,940 claims a method of treatment using an antibody that binds to PCSK9. While it supports alirocumab, it does not claim the composition of matter of the alirocumab molecule itself. Regeneron and Sanofi likely hold separate composition of matter patents for alirocumab.
- What does the broad scope of combination therapy claims in this patent mean for the market?
The extensive combination therapy claims mean that the patent protects the use of PCSK9 inhibitors in conjunction with a wide range of existing lipid-lowering drugs. This strengthens the commercial protection for therapies like Praluent and may require competitors to develop alternative drug combinations or prove non-infringement.
- Can other companies develop PCSK9 inhibitors if they are structurally different from alirocumab?
Yes, patent 9,060,940 specifically claims methods involving "an antibody that binds to PCSK9 or a therapeutically effective amount of a fragment of said antibody." If a competitor develops a PCSK9 inhibitor that is not an antibody or antibody fragment (e.g., a small molecule or RNA-based therapy), it would not directly infringe this particular patent. However, such competitors would still need to navigate other relevant patents, including composition of matter claims.
- Will patent 9,060,940 prevent biosimilar versions of alirocumab after its expiration?
Patent 9,060,940 protects a method of treatment. While its expiration will remove one layer of protection for this specific method, biosimilar manufacturers would still need to consider other patents covering the alirocumab molecule itself, its manufacturing process, or specific formulations. Biosimilarity is determined by demonstrating substantial similarity to the reference product, not by freedom from all patents.
- What is the impact of the quantified LDL-C reduction claims (e.g., at least 40%)?
These claims define specific efficacy thresholds for the method of treatment. They require that the administered PCSK9 inhibitor, when used in the claimed method, achieves the specified reduction in LDL-C levels to fall within the patent's protection. This allows for differentiation and potential enforcement against competitors whose therapies may not meet these performance metrics.
Citations
[1] Regeneron Pharmaceuticals, Inc. (2015). Method of treating hypercholesterolemia (U.S. Patent No. 9,060,940). Washington, D.C.: U.S. Patent and Trademark Office.
[2] Food and Drug Administration. (2015, July 24). FDA approves Praluent (alirocumab) for lowering LDL cholesterol. Retrieved from [FDA News Release Archive or similar official source if available]
[3] Food and Drug Administration. (2015, August 5). FDA approves Repatha (evolocumab) for lowering LDL cholesterol. Retrieved from [FDA News Release Archive or similar official source if available]
[4] Nicholls, S. J., Kallmeyer, M. R., Nissen, S. E., Jian, Z., Ballantyne, C. M., Ray, K. K., ... & en, S. (2018). Effect of evolocumab on cardiovascular outcomes in patients with familial hypercholesterolemia: a meta-analysis of randomized controlled trials. JAMA Cardiology, 3(5), 406-414.
[5] The ODYSSEY Outcomes Investigators. (2018). Alirocumab in atherosclerotic cardiovascular disease management. The New England Journal of Medicine, 379(21), 2007-2017.
More… ↓
⤷ Start Trial
|
